ASH 2022: Efgartigimod Safe, Effective for Primary Immune Thrombocytopenia
Benefits include early and sustained increase in platelet counts through 24 weeks, with no new safety concerns in first phase 3 topline results
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.